Suppr超能文献

同种异体移植诱导的血管平滑肌细胞增殖:治疗移植血管病变的潜在靶点。

Allograft-induced proliferation of vascular smooth muscle cells: potential targets for treating transplant vasculopathy.

作者信息

Autieri Michael V

机构信息

Department of Physiology, Cardiovascular Research Group, Temple University School of Medicine, Philadelphia, PA 19140, USA.

出版信息

Curr Vasc Pharmacol. 2003 Mar;1(1):1-9. doi: 10.2174/1570161033386772.

Abstract

Despite advances in immunosuppressive drugs, coronary artery transplant vasculopathy (CATV) is the major cause of graft failure that limits long-term survival of cardiac transplantation. The pathogenesis of CATV involves a chronic immune response of the recipient to the donor vasculature in which activated recipient immune cells damage the endothelium and produce cytokines, resulting in vascular smooth muscle cell (VSMC) activation. Activated VSMC migrate from the media into the lumen, proliferate, and elaborate cytokines and matrix proteins, resulting in loss of lumen diameter and vascular contractility. Because of its extensive nature, interventions which are successful in patients with conventional coronary artery disease are often not applicable to the majority of patients with CATV. Although intended for immune suppression, many immunosuppressive agents owe at least part of their efficacy to their anti proliferative effects on VSMC, including rapamycin, mycophenolic acid, cyclosporin, calcium channel blockers, and HMG CoA reductase inhibitors. Because activation of VSMC is responsible for most of the obliterative arterial intimal thickening present in solid organ allografts, the induction of expression of a selected set of genes may reflect the status of acceptance of the vasculature by the recipient, and the activation, migration, and proliferation of VSMC represent potential points for therapeutic intervention. The risk of infection and malignancy associated with immunosuppressive therapy further promote the need to identify a molecular target which directly modulates the VSMC response to injury. This review will summarize the anti proliferative effects that immunosuppressive drugs have on VSMC proliferation. We will also describe efforts to define the genes which regulate the vascular response to allograft injury, and describe how some of these proteins may represent targets to reduce VSMC proliferation and attenuate CATV.

摘要

尽管免疫抑制药物取得了进展,但冠状动脉移植血管病变(CATV)仍是导致移植物衰竭的主要原因,限制了心脏移植的长期存活。CATV的发病机制涉及受体对供体血管系统的慢性免疫反应,其中活化的受体免疫细胞损伤内皮并产生细胞因子,导致血管平滑肌细胞(VSMC)活化。活化的VSMC从血管中层迁移到管腔,增殖并分泌细胞因子和基质蛋白,导致管腔直径减小和血管收缩性丧失。由于其广泛性,在传统冠状动脉疾病患者中成功的干预措施通常不适用于大多数CATV患者。尽管旨在进行免疫抑制,但许多免疫抑制剂的疗效至少部分归因于它们对VSMC的抗增殖作用,包括雷帕霉素、霉酚酸、环孢素、钙通道阻滞剂和HMG CoA还原酶抑制剂。由于VSMC的活化是实体器官同种异体移植物中大多数闭塞性动脉内膜增厚的原因,一组选定基因表达的诱导可能反映受体对血管系统的接受状态,而VSMC的活化、迁移和增殖代表了治疗干预的潜在靶点。与免疫抑制治疗相关的感染和恶性肿瘤风险进一步促使人们需要确定一个直接调节VSMC对损伤反应的分子靶点。本综述将总结免疫抑制药物对VSMC增殖的抗增殖作用。我们还将描述确定调节血管对同种异体移植物损伤反应的基因的努力,并描述其中一些蛋白质如何可能成为减少VSMC增殖和减轻CATV的靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验